Quantum Genomics

Equities

ALQGC

FR0011648971

Biotechnology & Medical Research

Market Closed - Euronext Paris 11:25:15 2024-04-26 am EDT 5-day change 1st Jan Change
0.1292 EUR +1.89% Intraday chart for Quantum Genomics +9.86% +21.89%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Quantum Genomics Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Quantum Genomics Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Quantum Genomics: negotiations with Vistacare terminated CF
Global markets live: Microsoft, Raytheon, JPMorgan, Credit Suisse... Our Logo
Quantum Genomics Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Quantum Genomics: advanced discussions with a partner CF
Quantum Genomics Ousts Board President; CEO Named Successor MT
Quantum Genomics' Hypertension Drug Firibastat Fails to Show Significant Efficacy in Late-Stage Trial MT
Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, Fresh and Is Redirecting to New Developments CI
Certain Shares of Quantum Genomics Société Anonyme are subject to a Lock-Up Agreement Ending on 24-OCT-2022. CI
Quantum Genomics Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Quantum Genomics Société Anonyme(ENXTPA:ALQGC) dropped from S&P Global BMI Index CI
Quantum Genomics Announces the Appointment of Its New Scientific Advisory Board CI
Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH CI
Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs CI
Quantum Genomics Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Quantum Genomics Société Anonyme announced that it expects to receive €15 million in funding from Otium Capital, Vatel Capital SAS CI
Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606 CI
Quantum Genomics Secures New Patents For Potential Heart Drug QGC606 MT
Quantum Genomics Announces Granting of New Patents Protecting QGC606 CI
Stéphane Cohen Joins Quantum Genomics as Director of Global Operations CI
Quantum Genomics Société Anonyme Signs an Exclusive License and Production Agreement with Julphar CI
Quantum Genomics Société Anonyme announced that it expects to receive $2 million in funding from Gulf Pharmaceutical Industries P.S.C. CI
Quantum Genomics Signs an Exclusive License Agreement with Teva Israel Ltd CI
Quantum Genomics : Starts Late-Stage Study For Hypertension Treatment In Asia MT
Chart Quantum Genomics
More charts
Quantum Genomics is a biotechnology company that specializes in the research and development of drugs for the treatment of cardiovascular diseases such as high blood pressure and heart failure. All sales are abroad.
More about the company
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
0.1292 EUR
Average target price
0.1 EUR
Spread / Average Target
-22.60%
Consensus
  1. Stock Market
  2. Equities
  3. ALQGC Stock
  4. News Quantum Genomics
  5. Quantum Genomics Ousts Board President; CEO Named Successor